6066 Phase II study of two doses of NGR-hTNF, a vascular targeting agent (VTA), combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens

Authors :: Claudio Bordignon
Alberto Sobrero
A. Pessino
D. Comandini
L. Orsino
Giuseppe Fornarini
F. Caprioni
E. Bennicelli
Antonio Lambiase
Valeria Andretta
Source :: European Journal of Cancer Supplements. 7:341
Publication Year :: 2009
Publisher :: Elsevier BV, 2009.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
Colorectal cancer
Capecitabine/oxaliplatin
Phases of clinical research
medicine.disease
chemistry.chemical_compound
chemistry
NGR-hTNF
Internal medicine
Vascular-targeting agent
Medicine
business

Full Text Access

Tools